VisionGate Announces an Exclusive Global License, Manufacturing and Supply Agreement for Iloprost, VisionGate’s Phase 2 Oral Lung Cancer Interception Drug
August 22, 2019 08:00 ET | VisionGate, Inc.
Seattle, WA, Aug. 22, 2019 (GLOBE NEWSWIRE) -- VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, announces that it has finalized an exclusive worldwide license...
VisionGate Announces Lung Cancer Prevention Trial Progress
January 29, 2019 11:32 ET | VisionGate, Inc.
Seattle, WA, Jan. 29, 2019 (GLOBE NEWSWIRE) -- VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, announces that it has selected PCI Pharma Services to provide...
VisionGate is Leveraging the Cell-CT™ Platform to Expand Cancer Diagnostics Services, Biopharmaceutical Services and Cancer Prevention Medicines
April 05, 2018 14:03 ET | VisionGate, Inc.
SEATTLE, WA, April 05, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce today the advancement of its breakthrough...
VisionGate® Showcases Advances in Lung Cancer Early Detection and Treatment at the World Conference on Lung Cancer
October 19, 2017 13:54 ET | VisionGate, Inc.
SEATTLE, WA, Oct. 19, 2017 (GLOBE NEWSWIRE) -- VisionGate, Inc. reported significant findings in three recent studies at the 18th annual World Conference on Lung Cancer (WCLC) hosted by the...